By comparing the tumour weight and size of the CTRL, NE, anti-PD-1 mAb and anti-PD-1 mAb + NE groups, we found that NE significantly reduced the therapeutic effect of anti-PD-1 mAb (Fig. 1d, e). The gene discussed is PDCD1; the disease is neoplasm.